Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Public ClinicalTrials.gov record NCT03175367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.
Study identification
- NCT ID
- NCT03175367
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Interventions
- Evinacumab Drug
- Matching placebo Drug
- Background Lipid Modifying Therapy (LMT) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2017
- Primary completion
- May 21, 2020
- Completion
- Dec 13, 2020
- Last update posted
- Feb 9, 2023
2017 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Office of Dr. John D Homan MD | Newport Beach | California | 92663-3668 | — |
| Preventive Cardiology Inc | Boca Raton | Florida | 33434 | — |
| Care Research Center Inc | Doral | Florida | 33166 | — |
| Florida Lipid Institute | Winter Park | Florida | 32792 | — |
| St. Vincent Medical Group, Inc | Indianapolis | Indiana | 46290 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| EMMC Northeast Cardiology Assocites | Bangor | Maine | 04401 | — |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Heart Health Cardiology | Grand Rapids | Michigan | 49546 | — |
| Minneapolis Heart Institute Foundation | Minneapolis | Minnesota | 55407 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Mt Sinai Ichan Medical Institute | New York | New York | 10029 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Rowan Diagnostic Clinic | Salisbury | North Carolina | 28144 | — |
| Capital Area Research, LLC | Camp Hill | Pennsylvania | 17011 | — |
| The University Of Texas Health Science Center Houston | Houston | Texas | 77030 | — |
| San Antonio Premiere Internal Medicine | San Antonio | Texas | 78220 | — |
| Clear Clinical Research, LLC | Schertz | Texas | 78154 | — |
| PharmaTex Research | Tyler | Texas | 75701 | — |
| Wasatch Clinical Research | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03175367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2023 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03175367 live on ClinicalTrials.gov.